KRAS

KRAS

KRAS is a small GTPase of the RAS family that functions as a molecular switch in signal transduction, controlling cell proliferation, differentiation, and survival. First identified through oncogenic alleles in studies by Michael Bishop and Harold Varmus and characterized biochemically in work involving Robert Weinberg and Pier Paolo Di Fiore, KRAS links receptor activation at the plasma membrane to downstream effectors including the MAPK and PI3K pathways. Mutations in KRAS are among the most common oncogenic events in human cancers, notably in pancreatic, colorectal, and lung malignancies studied at institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.

Structure and Function

KRAS encodes a 21 kDa protein composed of a conserved G-domain and a hypervariable region (HVR). Structural studies by groups at Cold Spring Harbor Laboratory and The Scripps Research Institute using X-ray crystallography and NMR revealed nucleotide-dependent conformations that distinguish the GTP-bound active state from the GDP-bound inactive state. The G-domain contains motifs termed Switch I and Switch II that mediate interactions with guanine nucleotide exchange factors (GEFs) like Son of Sevenless and GTPase-activating proteins (GAPs) such as Neurofibromin 1. The HVR undergoes post-translational lipid modifications including farnesylation catalyzed by Farnesyltransferase and palmitoylation, targeting KRAS to membranes studied in work at Johns Hopkins University and University of California, San Francisco.

Regulation and Signaling Pathways

KRAS activity is regulated by GEFs and GAPs that respond to upstream cues from receptor tyrosine kinases like Epidermal growth factor receptor and MET. Upon activation, KRAS engages multiple effector pathways: the RAF–MEK–ERK cascade involving RAF1 and MAP2K1, the PI3K–AKT axis with effectors such as PIK3CA and AKT1, and the RalGDS pathway linked to RALB and vesicular trafficking components identified by researchers at Max Planck Institute. Crosstalk with scaffold proteins like KSR1 and feedback regulators including DUSP6 modulate signal amplitude and duration, as documented in studies from Stanford University and Harvard Medical School.

Role in Development and Physiology

Physiologically, KRAS contributes to embryogenesis, tissue homeostasis, and stem cell biology. Mouse genetics from groups led by Tyler Jacks and Anton Berns demonstrated that KRAS is essential for early development and that its isoforms have non-redundant roles in organogenesis such as lung morphogenesis and intestinal crypt maintenance. KRAS signaling influences lineage specification in contexts examined at Massachusetts Institute of Technology and regulates metabolic processes tied to mitochondrial function described in collaborations with European Molecular Biology Laboratory. Modulation of KRAS pathways also affects wound healing and immune cell responses studied at Salk Institute and Rockefeller University.

KRAS Mutations and Cancer

Oncogenic KRAS mutations, predominantly at codons 12, 13, and 61, lock the protein in a GTP-bound active state, driving unrestrained signaling. Landmark clinical and molecular oncology studies at National Cancer Institute and Mayo Clinic established KRAS mutations as drivers in pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and non-small cell lung carcinoma, with prognostic and predictive implications addressed in trials at Memorial Sloan Kettering Cancer Center and multicenter consortia like The Cancer Genome Atlas. Specific alleles (e.g., glycine-to-aspartate substitutions) alter effector bias and therapeutic vulnerability; discoveries by teams at University of California, San Diego and University of Oxford revealed allele-specific phenotypes that impact metastasis, metabolic reprogramming, and tumor microenvironment interactions involving stromal components investigated at Cedars-Sinai Medical Center.

Diagnostic and Therapeutic Approaches

KRAS mutation testing is routine in precision oncology workflows at healthcare centers including Mayo Clinic and MD Anderson Cancer Center using next-generation sequencing platforms developed by companies such as Illumina and laboratories associated with Foundation Medicine. Therapeutic strategies evolved from indirect targeting of downstream effectors (e.g., MEK inhibitors evaluated by GlaxoSmithKline and Novartis) to direct covalent inhibitors for specific mutant alleles pioneered in work at Amgen and AstraZeneca. Immunotherapy combinations and synthetic lethal approaches exploiting vulnerabilities identified in screens at Broad Institute and Cold Spring Harbor Laboratory are under clinical evaluation at academic centers like Johns Hopkins University Hospital. Resistance mechanisms involving secondary mutations, pathway reactivation, and tumor heterogeneity are active areas of study in multicenter trials coordinated by European Society for Medical Oncology and American Association for Cancer Research.

Experimental Models and Research Tools

Experimental platforms for KRAS research include genetically engineered mouse models developed in laboratories of Tyler Jacks and Robert Vries, conditional alleles enabling tissue-specific activation, patient-derived xenografts propagated at The Jackson Laboratory, and organoid systems pioneered by teams at Hubrecht Institute and Hubert Curien. Biochemical assays, proximity labeling techniques from Stanford University groups, and CRISPR screens executed at Broad Institute facilitate mapping of KRAS interactomes and synthetic lethal partners. Structural drug discovery efforts leverage facilities at Diamond Light Source and European Synchrotron Radiation Facility, while consortiums such as International Cancer Genome Consortium aggregate genomic and clinical data to inform translational research.

Category:Oncogenes